New Anticancer Drugs: Fourth Annual Program Review Symposium on Phase I and II in Clinical Trials, Tokyo, Japan, June 5-6, 1978. US Japan Agreement on Cancer Research: Recent Results in Cancer Research, cartea 70
Editat de S. K. Carter, Y. Sakuraien Limba Engleză Paperback – 8 dec 2011
Din seria Recent Results in Cancer Research
- 5% Preț: 845.19 lei
- 5% Preț: 191.69 lei
- 5% Preț: 782.46 lei
- 5% Preț: 913.76 lei
- 5% Preț: 919.23 lei
- 5% Preț: 400.28 lei
- 15% Preț: 490.42 lei
- 5% Preț: 703.83 lei
- 5% Preț: 721.05 lei
- 5% Preț: 709.35 lei
- 5% Preț: 711.15 lei
- 5% Preț: 710.60 lei
- 5% Preț: 713.33 lei
- 5% Preț: 361.80 lei
- 5% Preț: 712.60 lei
- 5% Preț: 371.10 lei
- 5% Preț: 721.96 lei
- 5% Preț: 716.84 lei
- 5% Preț: 356.32 lei
- 5% Preț: 719.74 lei
- 5% Preț: 717.56 lei
- 5% Preț: 359.60 lei
- 5% Preț: 706.41 lei
- 5% Preț: 717.73 lei
- 5% Preț: 719.19 lei
- 5% Preț: 705.32 lei
- 5% Preț: 718.29 lei
- 5% Preț: 717.20 lei
- 5% Preț: 711.15 lei
- 5% Preț: 712.25 lei
- 5% Preț: 710.96 lei
- 5% Preț: 378.97 lei
- 5% Preț: 1089.68 lei
- 5% Preț: 361.06 lei
- 5% Preț: 712.25 lei
- 5% Preț: 715.55 lei
- 5% Preț: 716.84 lei
- 5% Preț: 720.68 lei
- 5% Preț: 707.86 lei
- 5% Preț: 732.01 lei
- 5% Preț: 715.91 lei
- 5% Preț: 723.05 lei
- 5% Preț: 369.10 lei
- 5% Preț: 709.35 lei
- 5% Preț: 712.60 lei
- 5% Preț: 711.52 lei
- 5% Preț: 719.38 lei
- 5% Preț: 709.14 lei
- 5% Preț: 710.06 lei
- 5% Preț: 724.70 lei
Preț: 715.00 lei
Preț vechi: 752.63 lei
-5% Nou
Puncte Express: 1073
Preț estimativ în valută:
136.83€ • 142.67$ • 113.72£
136.83€ • 142.67$ • 113.72£
Carte tipărită la comandă
Livrare economică 20 martie-03 aprilie
Preluare comenzi: 021 569.72.76
Specificații
ISBN-13: 9783642813948
ISBN-10: 3642813941
Pagini: 248
Ilustrații: XII, 232 p. 5 illus.
Dimensiuni: 170 x 244 x 13 mm
Greutate: 0.4 kg
Ediția:Softcover reprint of the original 1st ed. 1980
Editura: Springer Berlin, Heidelberg
Colecția Springer
Seria Recent Results in Cancer Research
Locul publicării:Berlin, Heidelberg, Germany
ISBN-10: 3642813941
Pagini: 248
Ilustrații: XII, 232 p. 5 illus.
Dimensiuni: 170 x 244 x 13 mm
Greutate: 0.4 kg
Ediția:Softcover reprint of the original 1st ed. 1980
Editura: Springer Berlin, Heidelberg
Colecția Springer
Seria Recent Results in Cancer Research
Locul publicării:Berlin, Heidelberg, Germany
Public țintă
ResearchCuprins
of U.S.-Japan Joint Meeting on Phase I and II Clinical Trials.- The New NCI Screen and Its Implications for Clinical Evaluation.- The National Cancer Institute’s Natural Products Antineoplastic Development Program.- Methodology of Phase I Study in Japan.- Methodology of Phase II Clinical Trial in Cancer.- Phase II Study of Antineoplastic Agents in Japan.- Clinical Strategy for Evaluation of Anthracycline Analogues.- Preliminary Clinical Study of Aclacinomycin A.- Preclinical and Clinical Studies on Chlorozotocin, a New Nitrosourea with Decreased Bone Marrow Toxicity.- Continuation of Phase II Study of 1-(4-Amino-2-Methylpyrimidine-5-yl)-Methyl-3-(2-Chloroethyl)-3-Nitrosourea Hydrochloride (ACNU).- Review of Experimental Studies on Nitrosourea Derivates in Japan.- The Clinical Evaluation of Analogues, IV. Nitrosoureas.- Review of a New Antimetabolic Agent, 1-Hexylcarbamoyl-5-Fluorouracil (HCFU).- Review of a New Antimetabolic Agent, 1,1-Bis(Tetrahydro-2-Furanyl)-5-Fluoro-2,4-Pyrimidinedione (FD-1).- Effect and Mode of Action of N4-Behenoyl-?-D-Arabinofuranosylcytosine.- Strategy for Evaluation of a New Antitumor Agent in the Treatment of Breast Cancer.- Current Status of Breast Cancer Chemotherapy in Japan.- Present Status of Lung Cancer Chemotherapy in Japan.- Clinical Strategies in the Chemotherapy of Gastrointestinal Cancer.- Clinical Evaluation Strategy in Specific Disease Types — Clinical Study of Gastrointestinal Cancer Chemotherapy in One Institute of Japan.- A Review of Therapeutic Strategies for Phase I-II Trials in Genitourinary Cancer.- Recent Results of Using a Sequential Combination of Bleomycin and Mitomycin C in the Treatment of Metastatic Cervical Cancer.- Pharmacologic and Clinical Studies of N4-Behenoyl-1-Beta-D-Arabinofuranosylcytosine.